Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.
暂无分享,去创建一个
[1] Shokei Kim,et al. Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. , 1995, Circulation.
[2] M. Cairns,et al. Nucleic acid mutation analysis using catalytic DNA. , 2000, Nucleic acids research.
[3] J. Isner,et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. , 1997, Circulation.
[4] N. Usman,et al. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. , 2000, The Journal of clinical investigation.
[5] B. Dash,et al. Targeted cleavage of HIV‐1 envelope gene by a DNA enzyme and inhibition of HIV‐1 envelope‐CD4 mediated cell fusion , 1998, FEBS letters.
[6] S. Schwartz,et al. Antisense therapy for angioplasty restenosis. Some critical considerations. , 1995, Circulation.
[7] J. Rossi,et al. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). , 1999, Human gene therapy.
[8] G. F. Joyce,et al. A general purpose RNA-cleaving DNA enzyme. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[9] Ruo-Pan Huang,et al. UV irradiation upregulates Egr‐1 expression at transcription level , 1999, Journal of cellular biochemistry.
[10] E. Silverman,et al. Vascular smooth muscle cells express the transcriptional corepressor NAB2 in response to injury. , 1999, The American journal of pathology.
[11] Eileen D. Adamson,et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization , 1988, Cell.
[12] R. Kalb,et al. Sequence‐specific cleavage of Huntingtin mRNA by catalytic DNA , 1999, Annals of neurology.
[13] K. Taira,et al. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome. , 1999, Chemistry & biology.
[14] E. Topol,et al. Frontiers in interventional cardiology. , 1998, Circulation.
[15] C. Stein. Controversies in the cellular pharmacology of oligodeoxynucleotides. , 1997, Antisense & nucleic acid drug development.
[16] P. Teirstein,et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.
[17] G. F. Joyce,et al. Mechanism and utility of an RNA-cleaving DNA enzyme. , 1998, Biochemistry.
[18] M. Cairns,et al. Suppression of Smooth Muscle Cell Proliferation by a c-myc RNA-cleaving Deoxyribozyme* , 1999, The Journal of Biological Chemistry.
[19] V. Sukhatme,et al. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. , 1995, Progress in nucleic acid research and molecular biology.
[20] T. Jarvis,et al. Adenovirus-Mediated Expression of a Ribozyme to c-mybmRNA Inhibits Smooth Muscle Cell Proliferation and Neointima Formation In Vivo , 1999, Journal of Virology.
[21] L. Khachigian,et al. Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. , 1999, The American journal of pathology.
[22] Amyj . Williams,et al. Inducible PDGF A-chain transcription in smooth muscle cells is mediated by Egr-1 displacement of Sp1 and Sp3. , 1997, The American journal of physiology.
[23] J. Campbell,et al. Growth factors released into the coronary circulation after vascular injury promote proliferation of human vascular smooth muscle cells in culture. , 1997, Journal of the American College of Cardiology.
[24] A. Banerjea,et al. Sequence specific cleavage of the HIV‐1 coreceptor CCR5 gene by a hammer‐head ribozyme and a DNA‐enzyme: inhibition of the coreceptor function by DNA‐enzyme , 1998, FEBS letters.
[25] J. Brophy. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. , 2000, The New England journal of medicine.
[26] A. Karpeisky,et al. Chemical Modification of Hammerhead Ribozymes , 1995, The Journal of Biological Chemistry.
[27] B. Hicke,et al. Escort aptamers: a delivery service for diagnosis and therapy. , 2000, The Journal of clinical investigation.
[28] T. Applegate,et al. DzyNA-PCR: use of DNAzymes to detect and quantify nucleic acid sequences in a real-time fluorescent format. , 2000, Clinical chemistry.
[29] L. Khachigian,et al. Vascular smooth muscle cell proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent. , 1999, The American journal of pathology.
[30] L. Khachigian,et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury , 1999, Nature Medicine.
[31] R. Ross. The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.
[32] H. Ling,et al. Inhibition of infection of incoming HIV‐1 virus by RNA‐cleaving DNA enzyme , 1999, FEBS letters.
[33] W Rutsch,et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.
[34] M. Sioud,et al. Design of nuclease resistant protein kinase calpha DNA enzymes with potential therapeutic application. , 2000, Journal of molecular biology.
[35] B. Sullenger,et al. Developing aptamers into therapeutics. , 2000, The Journal of clinical investigation.
[36] T. Cech,et al. Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of tetrahymena , 1982, Cell.
[37] M. Cybulsky,et al. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. , 2000, The Journal of clinical investigation.
[38] Amyj . Williams,et al. Egr-1-Induced Endothelial Gene Expression: A Common Theme in Vascular Injury , 1996, Science.
[39] L. Khachigian,et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury , 1999, Nature Medicine.
[40] J. Milbrandt,et al. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli , 1996, Molecular and cellular biology.
[41] S. Asano,et al. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. , 1997, Nucleic acids research.
[42] J. Forrester,et al. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. , 1999, Circulation.
[43] P. Teirstein,et al. Prevention of coronary restenosis. , 1999, Cardiology in review.
[44] O. Uhlenbeck,et al. Self‐cleaving catalytic RNA , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] J. Gunn,et al. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. , 1997, Circulation research.
[46] J. Milbrandt,et al. Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[47] L. Khachigian,et al. Acute Local Release of Fibroblast Growth Factor-2 but not Transforming Growth Factor-β1 following Coronary Stenting , 2001, Thrombosis and Haemostasis.
[48] P. Nicod,et al. Editorial Comment Explosive Growth of Coronary Angioplasty Success Story of a Less Than Perfect Procedure , 1993, Circulation.
[49] T. Collins,et al. GC factor 2 represses platelet-derived growth factor A-chain gene transcription and is itself induced by arterial injury. , 1999, Circulation research.